- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02153255
Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa
Mucopolysaccharidosis Type IVa (MPS IVa, Morquio Disease) is a rare inherited lysosomal storage disorder caused by deficiency of the enzyme galactose-6-sulfatase.
Children with this disease accumulate a chemical called keratan sulphate, which stops their skeletons developing properly. They are very short in stature and many of their joints are unstable. Children with MPS IVa walk in a different way to other people due to a combination of lax ligaments and skeletal problems such as knock-knees.
Human walking involves the coordinated movements of all four limbs. As we walk, the arms swing oppositely to the legs. This movement pattern is very different in children with MPS IVa. This change seems to involve the whole musculoskeletal system and depends on the severity of the disease.
Recent studies in children with MPS IVa describing walking pattern have concentrated solely on the lower or upper limb respectively, and have not looked at the interaction of the upper and lower limbs during walking.
To our knowledge, the mechanics of walking in children with MPS IVa has not been investigated using a dynamic gait analysis tool (using cameras, sensors and electrodes to track the movements of different parts of the body during walking) and we aim to characterise this in a small number of children with MPS IVa and also examine the effects of splinting the wrist upon the walking pattern to see if this simple intervention makes it easier or more difficult for children with MPS IVa to walk.
Study Overview
Status
Conditions
Study Type
Contacts and Locations
Study Locations
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B4 6NH
- Birmingham Children's Hospital NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed diagnosis of MPS IVa (documented history of reduced leucocyte GALNS enzyme activity relative to the normal range of the laboratory performing the assay AND/OR molecular analysis showing two pathogenic mutations in the GALNS gene)
- Willing and able to provide written assent and parent/legal guardian able to provide written informed consent after the nature of the study has been explained and prior to any research-related procedures
- Between 6 and 18 years of age inclusive
- Willing to perform all study procedures as far as physically possible
Exclusion Criteria:
- Inability to comply with Gait Analysis protocol (e.g. nonambulant)
- Recent orthopaedic surgery that investigator deems might impact on Gait Analysis
- Use of any investigational product or investigational medical device other than BMN110 within 30 days prior to recruitment, or requirement for any investigational agent other than BMN110 prior to completion of all scheduled study assessments
- Concurrent disease or condition that would interfere with study participation or safety
- Any condition that, in the view of the Principal or Subinvestigators, places the subject at high risk of not completing the study procedures
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Children With Mucopolysaccharidosis Type IVa
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidence of abnormal walking pattern and surface EMG activity as assessed by Dynamic Gait Analysis
Time Frame: Within 6 months of recruitment
|
Assessment of head, trunk and joint positions during walking using a 12 camera Vicon motion analysis system.
Surface EMG analysis using a 16 channel wireless surface electromyographic (sEMG) system.
Assessment of lower limb joint moments and powers using Kistler 9281 and AMTI OPT 400600 force plates.
|
Within 6 months of recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gait pattern over one year
Time Frame: 12 months after first analysis
|
Comparison of two gait analysis studies taken 12 months apart
|
12 months after first analysis
|
Effect on gait pattern of using wrist splints
Time Frame: Within 6 months of recruitment
|
Assessment of repeat gait analysis measurements done at first visit whilst wearing wrist splints
|
Within 6 months of recruitment
|
Effect on gait pattern of lower limb surgery
Time Frame: Within 3 and 6 months of any lower limb surgery
|
Further gait analysis studies will be done if a child undergoes any lower limb orthopaedic surgery during the study period and compared with pre-surgery analyses
|
Within 3 and 6 months of any lower limb surgery
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Bone Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Bone Diseases, Developmental
- Mucopolysaccharidoses
- Osteochondrodysplasias
- Mucopolysaccharidosis IV
Other Study ID Numbers
- 14/WM/0120
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucopolysaccharidosis IV
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VIIUnited States, Canada
-
Hospital de Clinicas de Porto AlegreThe Isaac FoundationActive, not recruitingMucopolysaccharidoses | Mucopolysaccharidosis VI | Morquio A Syndrome | Mucopolysaccharidosis IV A | MPS IV A | MPS VI | MPS - Mucopolysaccharidosis | Morquio Syndrome A | Morquio SyndromeBrazil
-
Children's Hospitals and Clinics of MinnesotaBioMarin Pharmaceutical; Gillette Children's Specialty Healthcare; Greenwood...CompletedMucopolysaccharidosis VI | Mucopolysaccharidosis IV AUnited States
-
GOIZETBioMarin PharmaceuticalRecruiting
-
BioMarin PharmaceuticalTerminatedMorquio A Syndrome | MPS IV A | Mucopolysaccharidosis IVAUnited Kingdom
-
BioMarin PharmaceuticalICON plcCompletedMucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVAUnited States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
-
BioMarin PharmaceuticalCompletedMorquio A Syndrome | MPS IVA | Mucopolysaccharidosis IV AUnited States, Canada, France, Taiwan, Argentina, Colombia, Spain, Turkey, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, United Kingdom, Germany, Norway, Portugal, Italy, Qatar
-
Nadia Ali, PhDBioMarin PharmaceuticalCompletedMorquio A Syndrome | Mucopolysaccharidosis IV AUnited States
-
Nemours Children's ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVAUnited States
-
BioMarin PharmaceuticalTerminatedMorquio A Syndrome | MPS IV A | Mucopolysaccharidosis IVAFrance, United Kingdom, Taiwan, United States, Argentina, Netherlands, Canada, Brazil, Germany, Italy